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Despite current advancements in the field, management of older prostate cancer patients 
still remains a big challenge for Geriatric Oncology. The International Society of Geriatric 
Oncology (ISGO) has recently updated its recommendations in this area, and these have 
been widely adopted, notably by the European Association of Urology. This article out-
lines the principles that should be observed in the management of elderly patients who 
have recently undergone prostatectomy for malignancy or with a biochemical relapse fol-
lowing prostatectomy. Further therapeutic intervention should not be considered in those 
patients who are classified as frail in the geriatric assessment. In patients presenting 
better health conditions, salvage radiotherapy is to be preferred to adjuvant radiotherapy, 
which is only indicated in certain exceptional cases. Radiotherapy of the operative bed 
presents a higher risk to the elderly. Additionally, hormone therapy clearly shows higher 
side effects in older patients and therefore it should not be administered to asymptom-
atic patients. We propose a decision tree based on the ISGO recommendations, with 
specific modifications for patients in biochemical relapse.
Keywords: post-operative radiotherapy, prostate cancer, elderly patients, geriatric assessment, adjuvant 
radiotherapy, salvage radiotherapy
inTRODUCTiOn
Prostate cancer is the most common form of cancer in European and American men, particularly 
afflicting older patients by missing the target of an effective therapy quite often toward under-treatment 
(1–5). However, two large studies of non-curative approaches to prostate cancer have demonstrated, 
independently of age, that patients at low and intermediate risk have a lower specific mortality when 
compared to high-risk patients (64%) (6, 7) and therefore professional bodies are not following these 
directories (8, 9). Indeed, the importance of patient’s age is going to be considered, as reported by the 
recent recommendations of the European Association of Urology (EAU) (10). In the meantime, the 
International Society of Geriatric Oncology (ISGO) piloted a multi-disciplinary working group (of 
urologists, radiotherapists, medical oncologists, and geriatricians), delivering a set of guidelines for 
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the treatment of prostate cancer-affected elderly patients (based 
on the available literature), which were updated in 2013 (11, 12).
However, while this guidance addresses both localized pros-
tate cancers and metastatic disease, the question of post-operative 
radiotherapy was not addressed, nor the problem of biochemical 
relapse, though these are frequent scenarios in elderly patients. 
We propose here a revision of the model that addresses this 
particular situation.
wAiT AnD See POLiCY AnD BeST 
SUPPORTive CARe
The first question in a clinician’s mind when confronted with a 
patient presenting with high-risk pT3 prostate cancer with positive 
margins, detectable post-operative PSA levels, or a biochemical 
relapse, is the importance and relevance of all treatments, what-
ever they might be. The life expectancy of a patient at the time of 
biochemical relapse can be considerable (13). PSA doubling time 
and the initial Gleason score are the variables that are currently 
considered the best predictors of prostate cancer-specific mortality 
(14–16). In an illustrative study, Antonarakis followed a series of 
450 patients in biochemical relapse, observing a metastasis-free 
survival rate (MFS) at 10 years of 94% (Gleason score 4–6) and 
19% (Gleason score 8–10). In those cases where the PSA doubling 
time (PSA DT) was more than 15 months, the MFS rate reached 
the 72%, in contrast to those where the PSA DT was less than 
9 months (7% only) (17). Indeed, tumor aggressiveness and spe-
cific mortality risks should be discussed between urologists and 
radiation oncologists and integrated with a general onco-geriatric 
opinion regarding patient’s conditions or any existing co-morbidity 
(as specifically recommended by the new paragraph in the EAU 
guidance). Therefore, further therapeutic interventions should 
be considered only in patients presenting an aggressive prostate 
cancer (Gleason score ≥8 and/or short PSA DT), in accordance 
with a geriatric opinion. If any decision will be taken at this regard, 
the choice of therapy and its timing is the next consideration.
ADJUvAnT OR eARLY SALvAGe 
RADiOTHeRAPY FOR OLDeR PATienTS
The rationale for post-operative irradiation is addressed to eradi-
cating any microscopic residual of tumor after prostatectomy. In 
case of a detectable disease (a treatable PSA level), such therapy is 
termed “salvage radiotherapy (SRT),” while in cases where there 
are concerns about the completeness of the surgical resection, 
either positive excision margins or capsular rupture, though with 
sub-treatable PSA levels, the therapy would be termed “adjuvant 
radiotherapy” (ART).
For high-risk prostate cancers (pT3, R1), three large trials have 
validated the use of ART with respect to follow-up in terms of 
survival with no biochemical relapse: EORTC 22911, ARO 9602, 
and SWOG 8794 [reviewed in Thoms et al. (18–21)]. In the EORTC 
trial, 5-year survival without biochemical relapse was 77% in the 
ART arm against 55% in controls (which included patients who had 
late SRT). However, the survival data from these trials in patients 
with distant metastases are inconsistent. Of the three trials, only 
the EORTC trial specifically analyzed the data with respect to age, 
though patients older than 75 years were excluded from the trial. 
Patients over 70 years nevertheless represented 20% of all patients 
recruited (196/1,105 of whom 94 patients were in the radiotherapy 
arm and 102 in the control arm), against the 47% who were under 
65 years old. It is important to note that it was only in this over-70 
patient group that survival without biochemical relapse was not 
improved by adjuvant treatment compared with watchful waiting. 
This study also showed that ART clearly led to worse outcomes for 
the over-70 group in terms of survival free from clinical relapse 
[HR = 1.78 (1.14–2.78), p = 0.0003] and overall survival [HR = 2.94 
(1.75–4.93), p = 0.0008]. The criterion of age was the only signifi-
cant predictor among the many survival variables studied, which 
included PSA level, resection margins, extra-capsular invasion, 
invasion into the seminal vesicles, and pT staging.
Three multi-center randomized controlled trials are currently 
underway (GETUG 17, RAVES, and RADICALS), comparing 
immediate ART with radiotherapy according to biochemical 
parameters, with no upper age limit for study inclusion. Until these 
trials report (which will not be for several further years), the cur-
rent recommendation for elderly patients is to refrain from ART, 
but to consider SRT early, should the PSA rise above 0.2 ng/ml, 
whereas younger patients may benefit more from ART (20, 22).
SALvAGe RADiOTHeRAPY: 
eFFeCTiveneSS AnD ADveRSe eFFeCTS
Salvage radiotherapy is the only potentially curative treatment 
available in biochemical relapse. Early SRT is thought to prevent 
tumor progression in around half of patients (23). In the study by 
Stephenson, 501 patients (between 40 and 79 years at the time of 
their prostatectomy procedure) were given SRT, and 50% were 
relapse-free at 4 years. For patients with progressive disease, the 
median time to progression (TTP) was 12.5 months. It should be 
noted that this analysis does not take account of the age of the 
patients. This author has also developed a predictive model of 
relapse-free survival (biochemical or clinical) within 6 years of 
SRT (15). The model was developed using a retrospective series 
of 1,540 patients between 58 and 67 years at the time of prosta-
tectomy (though with no age data at the time of irradiation). The 
relevant variables in this nomogram are: PSA level before SRT, 
Gleason score, PSA DT, surgical margins, lymph node status, and 
the administration of hormonal treatment before or after SRT. 
This nomogram, which is suitable for patients of all ages, may 
assist decision-making when the PSA level is rising.
Radiotherapy to the prostatic bed can have long-term adverse 
effects. In the EORTC study, late grade 3 complications (from all 
sources) occurred in 5.3% of cases (compared with 2.5% in the 
observation arm, p = 0.052) with all genitourinary toxicity of grade 
≥2 at 21% (compared with 13% in the observation arm, p = 0.003), 
though no significant difference in gastro-intestinal toxicity of 
grade ≥2 were observed (2.5 versus 1.9%, p = 0.47) (18). These 
potential late complications are mainly urethral stenosis, urinary 
incontinence, and rectal bleeding. They were not specifically 
analyzed with respect to patient age. However, there are reasons 
to believe that SRT leads to fewer late side effects than ART. In a 
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large multi-center retrospective study of 959 patients treated with 
radiotherapy to the prostatic bed, ART independently predicted 
late urinary toxicity of grade 2 or greater compared with SRT (24). 
This study reminds us of the importance of a delay between pros-
tatectomy and irradiation to maximize sphincter recovery, recom-
mending an interval of at least 2 years in order to minimize the risk 
of late complications. It seems that post-operative radiotherapy 
leads to a greater number of adverse effects in elderly patients com-
pared with their younger counterparts (25–27) (see Table 1). In 
another retrospective study of 742 patients, the age and the dose of 
radiation were the most relevant parameters for predicting grade 
3 urinary toxicity in the long term (8 years) (25). The mean age at 
the time of radiotherapy was 65 years, with 117 patients less than 
72 years and 69 patients aged over 71 years. Grade 3 urinary toxicity 
occurred in 16% of patients aged over 71 years, in comparison with 
6% aged less than 72 years (p = 0.006). In a multivariate analysis, 
age was in independent prognostic predictor of long-term grade 3 
urinary toxicity, with an HR of 4.26 (1.45–12.47), p = 0.004.
We have not yet raised the question of hypofractionated treat-
ment. In prostate cancer, and particularly in the elderly patient, 
increasing the dose of radiation in each fraction, whilst reducing 
the number of sessions, is an attractive concept. Retrospective 
studies have evaluated the potential risks of increased toxicity 
associated with hypofractionation and studies are under way 
to evaluate its effectiveness and the potential risks of increased 
toxicity associated with hypofractionation (28, 29).
AnDROGen-DePRivATiOn THeRAPY
Patients presenting a localized prostate cancer who are currently 
considered ineligible for a curative local therapy (though most often 
the radiotherapist or urologist uses “intuitive criteria” to make this 
decision) are often offered androgen-deprivation therapy (ADT) 
instead. Scientifically, there is no evidence of benefit in survival to 
giving early treatment (30, 31). It is therefore currently advised to 
treat these patients only if they become symptomatic, except for 
patients who present with rapidly progressive disease (PSA DT 
<12 months). However, this evidence is balanced in practice by the 
concerns of patients, who, knowing that their PSA is climbing, are 
often very demanding that some treatment have to be instituted. 
It is important to note that very few patients are then referred for 
an onco-geriatric assessment, and that local treatment is judged 
more hazardous than hormone therapy. However, the long-term 
adverse effects of hormone therapy are now well-recognized and 
of particular concern in the elderly (32). Such adverse effects 
include bone demineralization (33), increased fracture risk (34, 
35), and increased cardio-vascular risk (36, 37). Several studies 
have found that patients rapidly decline physically, with marked 
effect on the quality of life, when treated with hormone therapy 
(38). Numerous physical activity programs have been devised to 
limit this, with very encouraging results (39–41). The other option 
to improve tolerability is to give intermittent hormone therapy 
rather than continuous treatment (42). This therapeutic strategy 
has been found to be equivalently effective, and is associated with 
a reduction in the unwanted effects of hormone therapy in several 
trials, notably in one of the largest trial, that of Calais da Silva, 
which recruited more than 900 patients and was also confirmed 
in a meta-analysis published by Shaw (43, 44).
It is also important to underline that, in practice, brief hormone 
therapy can be used alongside SRT. In high-risk localized cancers, 
a combination of radiotherapy and hormone therapy has generally 
been found to be more effective in comparison with radiotherapy 
alone (45). Among these trials, it should be noted that the 85.31 trial 
organized by the RTOG, included patients whose pT3a or b stage 
disease had been operated on, representing around 15% of the total 
number of 977 patients recruited to the study (46). The authors of 
this trial also concluded that combined radiotherapy and hormone 
therapy was superior, both in terms of overall survival (39 versus 49%, 
p = 0.002) and disease-specific mortality (16 versus 22%, p = 0.005). 
Similarly, post-operative radiotherapy combined with ADT may 
represent the new standard in the near future, based on the results 
of different clinical trials such as RTOG 9601, RTOG 0534, GETUG 
16, and GETUG 22 trials (47). However, the risk of cumulative 
toxicity following the two treatments has to be considered. Mature 
results of these different trials are needed prior to concluding that all 
biochemically relapsing prostate cancer patients need to be treated 
with prostate bed radiotherapy and 6-month ADT.
GeRiATRiC ASSeSSMenT AnD iSGO 
GUiDeLineS
It is currently considered that a patient will benefit from local 
treatment for his prostate disease if his life expectancy exceeds 
10 years. But life expectancy is not only determined by age. This 
is why it is fundamentally necessary to conduct an evaluation 
that takes into consideration co-morbidities, independent liv-
ing, nutritional status, cognitive function, and other important 
predictors of death not linked to the cancer of the elderly 
patient in localized prostate cancer, before making treatment 
decisions. Among the multi-dimensional geriatric evaluations 
used in onco-geriatrics, several tools and scoring systems have 
been developed. The burden of co-morbidities can be assessed 
using the Charlson score, or preferably, the Cumulative Illness 
Score Rating-Geriatrics (CIRS-G) (48). In that study of 2,273 
patients whose prostate cancer was treated with the objective of 
cure, a CIRS-G score of 1 translated into a relative risk of death 
within 10 years from another cause than prostate cancer of 1.64 
(1.52–1.76), when compared with a CIRS-G score of 0. The 
TABLe 1 | Post operative radiotherapy adverse events according to age.
Reference n Adverse event 
studied
cut off 
(years)
Hazard ratio/
odds ratio
Cozzarini et al. 
(2012) (25)
742 G3 long-term GU 
complications
71 HR = 4.26 
(1.45–12.47), 
p = 0.004
Longobardi  
et al. (2011) (26)
2011
178 ≥G2 acute bowel 
complications
66 OR = 4 (0.9–18.6), 
p = 0.08*
Perna et al. 
(2010) (27)
96 ≥G2 acute bowel 
complications
Continuous OR = 1.13 (1.02–
1.25), p = 0.021
*This study designated p < 0.1 as significant.
GU: Genito-urinary
TABLe 2 | OnCODAGe scoring chart for establishing G8 score.
Has the patient lost his appetite? Has he eaten less in the last 3 months 
because of poor appetite, gastro-intestinal symptoms, dysphagia, or 
problems with mastication?
0: Severe anorexia
1: Moderate anorexia
2: No anorexia
Recent weight loss (in the last 3 months)
0: Weight loss >3 kg
1: Not known
2: Weight loss >1 kg and <3 kg
3: No weight loss
Mobility
0: Bed-bound or wheelchair-bound
1: Mobile within the home
2: Independently mobile
neuropsychological problems
0: Severe dementia or depression
1: Moderate dementia or depression
2: No psychological problem
Body mass index (BMi)
0: BMI < 18.5
1: 18.5 ≤ BMI < 21
2: 21 ≤ BMI < 23
3: BMI ≥ 23
Taking more than three drugs
0: Yes
1: No
Does the patient consider his own health too be better or worse  
than others of his own age?
0: Less good
0.5: Don’t know
1: As good as others
2: Better than others
Age (years)
0: >85
1: 80–85
2: <80
Total 0–17
FiGURe 1 | SRT: Salvage radiotherapy; ADT: androgen deprivation 
therapy; BSC: best supportive care.
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relative risk rose by 1.18 (1.15–1.21) with each additional point 
gained using the scoring system. Independent living is assessed 
using the activities of daily living (ADL) and instrumental activi-
ties of daily living (IADL) scores (49, 50). In a study of 9,467 men 
and women over 70 years old, the survival rate at 10 years was 
54.2% in ADL score 0 patients (fully independent), versus 31.3, 
22.5, 16.7, and 4.2%, respectively, for ADL score groups 1–4 
(reflecting increasing dependence), differences which were all 
statistically significant (50). Nutritional status may be evaluated 
by using body weight, the rate of loss of body mass, and the 
Mini Nutritional Assessment (MNA) (51). For a MNA <17, the 
risk of death within a year is 50%, while that of patients with 
an MNA score between 17 and 23.5 is halved, at 25%. It is also 
important to evaluate cognitive functions and patients behavior 
systematically.
The onco-geriatric assessment enables the development of an 
accurate picture, which represents the patient’s overall condition, 
enabling appropriate interventions to be instituted where pos-
sible, such as the provision of help at home, the introduction of 
an anti-depressant, dietetic advice, and modification of the home 
environment. The outcome of this assessment is to place patients 
in one of three groups: fit, vulnerable (with potentially ameliora-
ble conditions), and frail (whose condition is irreversible) (52). 
Such thorough assessment is extremely time-consuming, and 
may not be possible in routine practice for every elderly patient 
who presents with prostate cancer. The G8, a geriatric rating 
instrument with only eight questions yielding up to 17 points, 
has been developed for screening in this situation (Table  2). 
Patients who score 14 or more are fit, and should be treated 
similarly to younger patients. Patients scoring ≤14 should ideally 
be referred for complete onco-geriatric assessment (53, 54). The 
usefulness of systematic onco-geriatric assessment has largely 
been demonstrated, by improving the patient’s overall condi-
tion, or by informing therapeutic decision-making (55–57). The 
International Society of Geriatric Oncology (SIOG) convened a 
multi-disciplinary working group of urologists, radiotherapists, 
medical oncologists, and geriatricians charged with reviewing the 
literature and produced a set of guidelines on the treatment of 
prostate cancer in elderly patients (11, 12). These guidelines were 
then adopted by the EAU in its specific section on the elderly 
patient. However, prostate cancers are dealt with in two categories 
depending on whether the disease presents with localized or 
metastatic disease. The guidelines do not specifically consider 
the problem of biochemical relapse, though it is a frequently 
encountered situation in routine clinical practice.
In the case of biochemical relapse following prostatectomy 
in patients over 70 years of age, we propose that the G8 screen-
ing questionnaire should be administered by the urologist, 
radiotherapist, or medical oncologist (Figure 1). If the G8 score 
is >14, the patient is considered fit and will be preferentially 
offered SRT if his PSA >0.2  ng/ml. (ART may be considered 
on a case by case basis in particularly aggressive disease). If the 
G8 score ≤14, the patient will be referred to the onco-geriatric 
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service for complete assessment. If this finds the patient to be 
vulnerable or frail, any treatable conditions should be addressed 
in order that the patient may benefit from SRT. If the patient is 
considered to be frail or unfit, with irreversible decline, sup-
portive care should be offered, and hormone therapy delayed as 
long as possible, to be used only in the advent of bony or urinary 
symptomatology.
COnCLUSiOn
Appropriate assessment and management of elderly patients with 
prostate cancer is a key issue. The appropriate balance between 
the risk of under-treatment (on the grounds of age alone), and 
the risk of adverse effects that may excessively compromise the 
patient’s general status and independence, must be determined 
for each patient. In practice, in the post-operative situation in the 
elderly patient, the following principles may be adopted:
- No ART except in exceptional cases, while favoring SRT.
- Radiotherapy of the prostate bed presents higher risk in the 
elderly patient compared with his younger counterpart.
- Hormone therapy as a monotherapy is clearly toxic to elderly 
patients, and should not be given in the absence of symptoms.
- Short-term Hormone therapy combined with salvage prostate 
bed radiotherapy may represent a new standard treatment in 
the near future, but more mature data from clinical trials are 
needed.
Onco-geriatrics has been a growth specialty for several years 
now, and professional bodies increasingly provide guidance 
specific to the needs of older patients. Nevertheless further onco-
geriatric trials remain necessary with the aim of establishing the 
place of more aggressive treatments such as SRT or hormone 
therapy in the treatment of elderly patients, compared with 
watchful waiting.
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